Immunoglobulins for preventing hepatitis A (Q24241613)

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis in army recruits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Pre-exposure prophylaxis of viral hepatitis with immune serum globulin in an endemic area. A trial in field units of the Israel Defence Forces

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Hepatitis A vaccine versus immune globulin for postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Prevention of endemic HAA-positive hepatitis with gamma globulin. Use of a simple radioimmune assay to detect HAA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Efficacy of immune serum globulin in an outbreak of hepatitis A virus infection in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Apparent effect of immune serum globulin prophylaxis in the military on viral hepatitis incidence in the civilian population in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Clinical and Subclinical Hepatitis a Occurring after Immunoglobulin Prophylaxis among Swedish UN Soldiers in Sinai

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

The cost of hepatitis A infections in American adolescents and adults in 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

CONSORT statement: extension to cluster randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

History and epidemiology of hepatitis A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Prion diseases: epidemiology in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Host immune response to hepatitis A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Do certain countries produce only positive results? A systematic review of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

Hepatitis prophylaxis abroad. Effectiveness of immune serum globulin in protecting Peace Corps volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

7 January 2021

Immunoglobulin prophylaxis against hepatitis A among Swedish UN soldiers in an endemic region

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

7 January 2021

Cost-effectiveness analysis of hepatitis A prevention in travellers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

1 reference

7 January 2021

Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

7 January 2021

Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

7 January 2021

The need for immunoglobulin for travelers who receive hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004181.PUB2

7 January 2021